Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

The development of a magnetic resonance imaging index for fistulising Crohn's disease.

Samaan MA, Puylaert CAJ, Levesque BG, Zou GY, Stitt L, Taylor SA, Shackelton LM, Vandervoort MK, Khanna R, Santillan C, Rimola J, Hindryckx P, Nio CY, Sandborn WJ, D'Haens G, Feagan BG, Jairath V, Stoker J.

Aliment Pharmacol Ther. 2017 Sep;46(5):516-528. doi: 10.1111/apt.14190. Epub 2017 Jun 27.

2.

Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis.

D'Haens GR, Sandborn WJ, Zou G, Stitt LW, Rutgeerts PJ, Gilgen D, Jairath V, Hindryckx P, Shackelton LM, Vandervoort MK, Parker CE, Muller C, Pai RK, Levchenko O, Marakhouski Y, Horynski M, Mikhailova E, Kharchenko N, Pimanov S, Feagan BG.

Aliment Pharmacol Ther. 2017 Aug;46(3):292-302. doi: 10.1111/apt.14164. Epub 2017 Jun 1.

3.

Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis.

Jairath V, Zou G, Parker CE, Macdonald JK, Mosli MH, Khanna R, Shackelton LM, Vandervoort MK, AlAmeel T, Al Beshir M, AlMadi M, Al-Taweel T, Atkinson NS, Biswas S, Chapman TP, Dulai PS, Glaire MA, Hoekman D, Koutsoumpas A, Minas E, Samaan MA, Travis S, D'Haens G, Levesque BG, Sandborn WJ, Feagan BG.

J Crohns Colitis. 2016 May;10(5):607-18. doi: 10.1093/ecco-jcc/jjw004. Epub 2016 Jan 7. Review.

4.

Development and validation of a histological index for UC.

Mosli MH, Feagan BG, Zou G, Sandborn WJ, D'Haens G, Khanna R, Shackelton LM, Walker CW, Nelson S, Vandervoort MK, Frisbie V, Samaan MA, Jairath V, Driman DK, Geboes K, Valasek MA, Pai RK, Lauwers GY, Riddell R, Stitt LW, Levesque BG.

Gut. 2017 Jan;66(1):50-58. doi: 10.1136/gutjnl-2015-310393. Epub 2015 Oct 16.

PMID:
26475633
5.

Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials.

Jairath V, Khanna R, Zou GY, Stitt L, Mosli M, Vandervoort MK, D'Haens G, Sandborn WJ, Feagan BG, Levesque BG.

Aliment Pharmacol Ther. 2015 Nov;42(10):1200-10. doi: 10.1111/apt.13408. Epub 2015 Sep 21.

6.

Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial.

Khanna R, Bressler B, Levesque BG, Zou G, Stitt LW, Greenberg GR, Panaccione R, Bitton A, Paré P, Vermeire S, D'Haens G, MacIntosh D, Sandborn WJ, Donner A, Vandervoort MK, Morris JC, Feagan BG; REACT Study Investigators.

Lancet. 2015 Nov 7;386(10006):1825-34. doi: 10.1016/S0140-6736(15)00068-9. Epub 2015 Sep 3.

PMID:
26342731
7.

Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease.

Khanna R, Zou G, D'Haens G, Rutgeerts P, McDonald JW, Daperno M, Feagan BG, Sandborn WJ, Dubcenco E, Stitt L, Vandervoort MK, Donner A, Luo A, Levesque BG.

Gut. 2016 Jul;65(7):1119-25. doi: 10.1136/gutjnl-2014-308973. Epub 2015 May 2.

PMID:
25935574
8.

Reproducibility of histological assessments of disease activity in UC.

Mosli MH, Feagan BG, Zou G, Sandborn WJ, D'Haens G, Khanna R, Behling C, Kaplan K, Driman DK, Shackelton LM, Baker KA, MacDonald JK, Vandervoort MK, Samaan MA, Geboes K, Valasek MA, Pai R, Langner C, Riddell R, Harpaz N, Sewitch M, Peterson M, Stitt LW, Levesque BG.

Gut. 2015 Nov;64(11):1765-73. doi: 10.1136/gutjnl-2014-307536. Epub 2014 Oct 30.

PMID:
25360036
9.

A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity.

Khanna R, Zou G, D'Haens G, Feagan BG, Sandborn WJ, Vandervoort MK, Rolleri RL, Bortey E, Paterson C, Forbes WP, Levesque BG.

Aliment Pharmacol Ther. 2015 Jan;41(1):77-86. doi: 10.1111/apt.13001. Epub 2014 Oct 27.

10.

Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices.

Mosli MH, Feagan BG, Sandborn WJ, Dʼhaens G, Behling C, Kaplan K, Driman DK, Shackelton LM, Baker KA, Macdonald JK, Vandervoort MK, Geboes K, Levesque BG.

Inflamm Bowel Dis. 2014 Mar;20(3):564-75. doi: 10.1097/01.MIB.0000437986.00190.71. Review.

PMID:
24412993
11.

Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease.

Feagan BG, McDonald JW, Panaccione R, Enns RA, Bernstein CN, Ponich TP, Bourdages R, Macintosh DG, Dallaire C, Cohen A, Fedorak RN, Paré P, Bitton A, Saibil F, Anderson F, Donner A, Wong CJ, Zou G, Vandervoort MK, Hopkins M, Greenberg GR.

Gastroenterology. 2014 Mar;146(3):681-688.e1. doi: 10.1053/j.gastro.2013.11.024. Epub 2013 Nov 21.

PMID:
24269926
12.

Simplified therapeutic intervention to control hypertension and hypercholesterolemia: a cluster randomized controlled trial (STITCH2).

Dresser GK, Nelson SA, Mahon JL, Zou G, Vandervoort MK, Wong CJ, Feagan BG, Feldman RD.

J Hypertens. 2013 Aug;31(8):1702-13. doi: 10.1097/HJH.0b013e3283619d6a.

PMID:
23743804
13.

The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis.

Feagan BG, Sandborn WJ, D'Haens G, Pola S, McDonald JWD, Rutgeerts P, Munkholm P, Mittmann U, King D, Wong CJ, Zou G, Donner A, Shackelton LM, Gilgen D, Nelson S, Vandervoort MK, Fahmy M, Loftus EV Jr, Panaccione R, Travis SP, Van Assche GA, Vermeire S, Levesque BG.

Gastroenterology. 2013 Jul;145(1):149-157.e2. doi: 10.1053/j.gastro.2013.03.025. Epub 2013 Mar 22.

PMID:
23528626
14.

A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease.

Sands BE, Katz S, Wolf DC, Feagan BG, Wang T, Gustofson LM, Wong C, Vandervoort MK, Hanauer S.

Gut. 2013 Sep;62(9):1288-94. doi: 10.1136/gutjnl-2011-300995. Epub 2012 Jul 3.

PMID:
22760005
15.

Barriers to blood pressure control: a STITCH substudy.

Nelson SA, Dresser GK, Vandervoort MK, Wong CJ, Feagan BG, Mahon JL, Feldman RD.

J Clin Hypertens (Greenwich). 2011 Feb;13(2):73-80. doi: 10.1111/j.1751-7176.2010.00392.x. Epub 2010 Dec 10.

16.

A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial.

Feldman RD, Zou GY, Vandervoort MK, Wong CJ, Nelson SA, Feagan BG.

Hypertension. 2009 Apr;53(4):646-53. doi: 10.1161/HYPERTENSIONAHA.108.123455. Epub 2009 Feb 23.

PMID:
19237683
17.

Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin.

Feagan BG, Greenberg GR, Wild G, Fedorak RN, Paré P, McDonald JW, Cohen A, Bitton A, Baker J, Dubé R, Landau SB, Vandervoort MK, Parikh A.

Clin Gastroenterol Hepatol. 2008 Dec;6(12):1370-7. doi: 10.1016/j.cgh.2008.06.007. Epub 2008 Oct 1. Erratum in: Clin Gastroenterol Hepatol. 2009 Apr;7(4):494.

PMID:
18829392
18.

A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis.

Sands BE, Sandborn WJ, Feagan B, Löfberg R, Hibi T, Wang T, Gustofson LM, Wong CJ, Vandervoort MK, Hanauer S; Adacolumn Study Group.

Gastroenterology. 2008 Aug;135(2):400-9. doi: 10.1053/j.gastro.2008.04.023. Epub 2008 Apr 25.

PMID:
18602921
19.

Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials.

Feagan BG, Sandborn WJ, Mittmann U, Bar-Meir S, D'Haens G, Bradette M, Cohen A, Dallaire C, Ponich TP, McDonald JW, Hébuterne X, Paré P, Klvana P, Niv Y, Ardizzone S, Alexeeva O, Rostom A, Kiudelis G, Spleiss J, Gilgen D, Vandervoort MK, Wong CJ, Zou GY, Donner A, Rutgeerts P.

JAMA. 2008 Apr 9;299(14):1690-7. doi: 10.1001/jama.299.14.1690.

PMID:
18398081
20.

A cluster-randomized controlled trial of a blood conservation algorithm in patients undergoing total hip joint arthroplasty.

Wong CJ, Vandervoort MK, Vandervoort SL, Donner A, Zou G, MacDonald JK, Freedman J, Karkouti K, MacDonald SJ, Feagan BG.

Transfusion. 2007 May;47(5):832-41.

PMID:
17465948
21.

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.

Feagan BG, Greenberg GR, Wild G, Fedorak RN, Paré P, McDonald JW, Dubé R, Cohen A, Steinhart AH, Landau S, Aguzzi RA, Fox IH, Vandervoort MK.

N Engl J Med. 2005 Jun 16;352(24):2499-507.

22.

The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. 1994 [classical article].

Noseworthy JH, Ebers GC, Vandervoort MK, Farquhar RE, Yetisir E, Roberts R.

Neurology. 2001 Dec;57(12 Suppl 5):S31-5. No abstract available.

PMID:
11902593
23.

Evaluation of portable bladder ultrasound: accuracy and effect on nursing practice in an acute care neuroscience unit.

O'Farrell B, Vandervoort MK, Bisnaire D, Doyle-Pettypiece P, Koopman WJ, McEwan L.

J Neurosci Nurs. 2001 Dec;33(6):301-9.

PMID:
11776712
24.

Treatment and outcomes of community-acquired pneumonia at Canadian hospitals.

Feagan BG, Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK.

CMAJ. 2000 May 16;162(10):1415-20.

25.

A critical pathway for treatment of community-acquired pneumonia

Feagan BG, Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK.

JAMA. 2000 May 24;283(20):2654-5. No abstract available.

PMID:
10819938
26.
27.

Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study.

Hahn AF, Bolton CF, Pillay N, Chalk C, Benstead T, Bril V, Shumak K, Vandervoort MK, Feasby TE.

Brain. 1996 Aug;119 ( Pt 4):1055-66.

PMID:
8813270
28.

The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial.

Noseworthy JH, Ebers GC, Vandervoort MK, Farquhar RE, Yetisir E, Roberts R.

Neurology. 1994 Jan;44(1):16-20.

PMID:
8290055
29.

An open-trial evaluation of mitoxantrone in the treatment of progressive MS.

Noseworthy JH, Hopkins MB, Vandervoort MK, Karlik SJ, Lee DH, Penman M, Rice GP, Grinwich KD, Cauvier H, Harris BJ, et al.

Neurology. 1993 Jul;43(7):1401-6.

PMID:
8327145
30.

Serial cranial and spinal cord magnetic resonance imaging in multiple sclerosis.

Wiebe S, Lee DH, Karlik SJ, Hopkins M, Vandervoort MK, Wong CJ, Hewitt L, Rice GP, Ebers GC, Noseworthy JH.

Ann Neurol. 1992 Nov;32(5):643-50.

PMID:
1449244
31.

Cyclophosphamide and plasma exchange in multiple sclerosis.

Noseworthy JH, Vandervoort MK, Penman M, Ebers G, Shumak K, Seland TP, Roberts R, Yetisir E, Gent M, Taylor DW.

Lancet. 1991 Jun 22;337(8756):1540-1. No abstract available.

PMID:
1675382
33.

Plasma exchange for MS.

Noseworthy JH, Vandervoort MK, Ebers GC.

Neurology. 1990 May;40(5):864-6. No abstract available. Erratum in: Neurology 1990 Jul;40(7):1153.

PMID:
2158638
34.

NMR studies in experimental allergic encephalomyelitis: factors which contribute to T1 and T2 values.

Karlik SJ, Gilbert JJ, Wong C, Vandervoort MK, Noseworthy JH.

Magn Reson Med. 1990 Apr;14(1):1-11.

PMID:
1693744
35.

Long-term use of antecubital veins for plasma exchange. The Canadian Cooperative Multiple Sclerosis Study Group.

Noseworthy JH, Shumak KH, Vandervoort MK.

Transfusion. 1989 Sep;29(7):610-3.

PMID:
2672434
36.

A referendum on clinical trial research in multiple sclerosis: the opinion of the participants at the Jekyll Island workshop.

Noseworthy JH, Vandervoort MK, Hopkins M, Ebers GC.

Neurology. 1989 Jul;39(7):977-81.

PMID:
2739925
37.

Acceptance of placebo-control trial design by progressive multiple sclerosis patients. The Canadian Cooperative Multiple Sclerosis Study Group.

Noseworthy JH, Vandervoort MK, Ebers GC.

Neurology. 1989 Apr;39(4):606-7. No abstract available.

PMID:
2648191
38.

The prevalence of primary Sjögren's syndrome in a multiple sclerosis population.

Noseworthy JH, Bass BH, Vandervoort MK, Ebers GC, Rice GP, Weinshenker BG, McLay CJ, Bell DA.

Ann Neurol. 1989 Jan;25(1):95-8.

PMID:
2913935
39.

Post-lumbar puncture headache: review of the literature and nursing implications.

Bass B, Vandervoort MK.

Axone. 1988 Mar;9(3):30-4. No abstract available.

PMID:
3348988
40.

Postnatal NMR changes in guinea pig central nervous system: potential relevance to experimental allergic encephalomyelitis.

Noseworthy JH, Gilbert JJ, Vandervoort MK, Karlik SJ.

Magn Reson Med. 1988 Feb;6(2):199-211.

PMID:
3367777

Supplemental Content

Loading ...
Support Center